News
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
23 Feb 24
Long Ideas, News, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
RBC Capital Maintains Outperform on Exelixis, Raises Price Target to $28
7 Feb 24
News, Price Target, Analyst Ratings
Recap: Exelixis Q4 Earnings
6 Feb 24
Earnings
Exelixis Q4 Adj EPS $0.33 Beats $0.22 Estimate, Sales $479.65M Miss $484.88M Estimate
6 Feb 24
Earnings, News
Earnings Scheduled For February 6, 2024
6 Feb 24
Earnings
Earnings Preview For Exelixis
5 Feb 24
Earnings
Stifel Maintains Hold on Exelixis, Raises Price Target to $25
2 Feb 24
News, Price Target, Analyst Ratings
Breaking Down Exelixis: 7 Analysts Share Their Views
30 Jan 24
Analyst Ratings
Barclays Maintains Overweight on Exelixis, Raises Price Target to $25
30 Jan 24
News, Price Target, Analyst Ratings
Exelixis Announces Detailed Results Of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib In Combination With Atezolizumab In Metastatic Castration-Resistant Prostate Cancer Presented At ASCO GU 2024
25 Jan 24
Biotech, News, General
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
23 Jan 24
Biotech, Large Cap, News, Health Care, General
Bristol-Myers Squibb Announced Opdivo In Combination With Cabometyx Demonstrates Long-term Survival Benefits After Four Years Of Follow-up In The Checkmate -9er Trial In First-line Advanced Renal Cell Carcinoma
22 Jan 24
News
10 Health Care Stocks Whale Activity In Today's Session
22 Jan 24
Options
Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell'
12 Jan 24
Long Ideas, News, Small Cap, Top Stories, Markets, Media, Trading Ideas
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
8 Jan 24
Analyst Color, Biotech, Earnings, Equities, Large Cap, News, Health Care, Reiteration, Markets, Analyst Ratings, Movers, Trading Ideas, General
Exelixis Announces Reducing Its Workforce By Approximately 175 Employees Or 13%; Expects To Substantially Complete The Restructuring In Q1 Of 2024 And Recognize A Restructuring Charge Of ~$25M
7 Jan 24
News, Management
Exelixis Announces The Board Of Directors Has Authorized A $450M Share Repurchase In 2024 After Successful Completion Of $550M Share Repurchase In 2023
7 Jan 24
News, Buybacks
Exelixis Announces Preliminary FY23 Financial Results, Provides 2024 Financial Guidance, And Outlines Key Priorities And Milestones For 2024; Sees FY23 Revenue Of $1.83B Vs $1.84B Est.; Sees FY24 Revenue $1.825B-$1.925B Vs $2.06B Est.
7 Jan 24
Earnings, News, Guidance
Press releases
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
27 Feb 24
Press Releases
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
14 Feb 24
Biotech, Press Releases, General
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
6 Feb 24
Press Releases
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
1 Feb 24
Press Releases
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
25 Jan 24
Press Releases
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
23 Jan 24
Press Releases
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
22 Jan 24
Press Releases
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
18 Jan 24
Press Releases
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
7 Jan 24
Press Releases
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
2 Jan 24
Press Releases